Mary Metz, APRN
Family · Lincoln, NENPI 1952065906
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Pfizer accounts for 73.0% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $10,692, more than ten times the $6 reported in 2021. Among family clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $74.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$9K
- AbbVie$914
- Lundbeck LLC$552
- UCB, Inc.$237
- Novartis$152
- Acadia Pharmaceuticals Inc$142
- plus $1K from 29 others
What the payments were for
- Consulting fees$1,35011%
- Speaking & faculty fees$7,62560%
- Travel & lodging$590%
- Food & beverage$3,75029%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 20 | $9,350 |
| AbbVie | 45 | $914 |
| Lundbeck LLC | 11 | $552 |
| UCB, Inc. | 10 | $237 |
| Novartis | 8 | $152 |
| Acadia Pharmaceuticals Inc | 7 | $142 |
| EMD Serono, Inc. | 7 | $137 |
| AstraZeneca(2 entities) | 7 | $126 |
| Eisai Inc. | 5 | $106 |
| Teva Pharmaceuticals USA, Inc. | 5 | $96 |
| Banner Life Sciences, LLC | 4 | $95 |
| Argenx US, Inc. | 3 | $86 |
| Amgen | 3 | $72 |
| Genentech USA, Inc. | 3 | $66 |
| Merz Pharmaceuticals, LLC | 2 | $59 |
| CSL Behring | 3 | $58 |
| ANI Pharmaceuticals, Inc. | 2 | $54 |
| Biogen | 3 | $52 |
| Lilly USA, LLC | 3 | $50 |
| SK Life Science, Inc. | 2 | $41 |
| Tonix Medicines, Inc. | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 2 | $35 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Boston Scientific | 1 | $30 |
| Catalyst Pharmaceuticals, Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Hospira, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| TG Therapeutics, Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $17 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| MDD US Operations, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$8,975
- VYEPTI$237
How this compares
$12,800 in reported general payments places this provider in the 95th percentile of 809 family providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuliptaAtogepant | 48 | $43,407 |
| Nurtec OdtRimegepant Sulfate | 41 | $42,465 |
| UbrelvyUbrogepant | 41 | $41,988 |
| Aimovig AutoinjectorErenumab-Aooe | 49 | $36,817 |
| Emgality PenGalcanezumab-Gnlm | 42 | $32,669 |
| XcopriCenobamate | 25 | $22,317 |
| BriviactBrivaracetam | 17 | $22,008 |
| VimpatLacosamide | 22 | $10,911 |
| Levetiracetam | 103 | $2,325 |
| Lamotrigine | 49 | $1,237 |
| DilantinPhenytoin Sodium Extended | 23 | $1,143 |
| Lacosamide | 33 | $879 |
| Memantine Hcl | 28 | $757 |
| Zonisamide | 12 | $611 |
| Divalproex Sodium ErDivalproex Sodium | 39 | $604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $914 | $85,39489 claims |
| PfizerNurtec Odt, Dilantin | $9,350 | $43,60864 claims |
| UCB, Inc.Briviact, Vimpat | $237 | $32,92039 claims |
| SK Life Science, Inc.Xcopri | $41 | $22,31725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Nebraska.
Other family in Lincoln
- Alyson FergusonLincoln$7K
- Mary GladeLincoln$7K
- Colleen CarpenterLincoln$5K
- Melany MurrayLincoln$5K
- Samantha NiceLincoln$5K
- Miranda PollmanLincoln$5K
- Marissa EbelLincoln$5K
- John GrandgenettLincoln$4K
- Chelsy BinkleyLincoln$4K
- Lori MalloryLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.